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Introduction
Both type 1 and type 2 diabetes are common and serious
disorders across the world, resulting in considerable morbidity
and mortality (1). Treatment of diabetes by insulin and/or oral
drugs fails to prevent these complications in clinical practice,
indicating the need for additional medication for diabetic
patients.
Tetrandrine (6,6 ,7,12-tetramethoxy-2,2 -dimethylberbam) is
a bisbenzyl tetrahydroisoquinoline alkaloid extracted from the
Chinese medicinal herb Radix Stephania tetrandrae, dry roots
of Stephaniae tetrandrine S. Moore (Menispermaceae), which
has been used traditionally as an analgesic and anti-hypertensive
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The role of  -endorphin in the plasma glucose-lowering action of tetrandrine in streptozotocin-induced
diabetic rats (STZ-diabetic rats) was investigated. The plasma glucose concentration was assessed by the
glucose oxidase method. The enzyme-linked immunosorbent assay was used to determine the plasma
level of  -endorphin-like immunoreactivity (BER). The mRNA levels of glucose transporter subtype 4
(GLUT4) in soleus muscle and phosphoenolpyruvate carboxykinase (PEPCK) in the liver of STZ-dia-
betic rats were detected by Northern blotting analysis. The expressed protein of GLUT4 or PEPCK was
characterized by Western blotting analysis. Tetrandrine dose-dependently increased plasma BER in a
manner parallel to the decrease of plasma glucose in STZ-diabetic rats. Moreover, the plasma glucose-
lowering effect of tetrandrine was inhibited by naloxone and naloxonazine at doses sufficient to block
opioid  -receptors. Further, tetrandrine failed to produce plasma glucose-lowering action in opioid 
 -receptor knockout diabetic mice. Bilateral adrenalectomy eliminated the plasma glucose-lowering
effect and plasma BER-elevating effect of tetrandrine in STZ-diabetic rats. Both effects were abolished
by treatment with hexamethonium or pentolinium at doses sufficient to block nicotinic receptors.
Tetrandrine enhanced BER release directly from the isolated adrenal medulla of STZ-diabetic rats and
this action was abolished by the blockade of nicotinic receptors. Repeated intravenous administration of
tetrandrine (1.0 mg/kg) to STZ-diabetic rats for 3 days resulted in an increase in the mRNA and protein
levels of the GLUT4 in soleus muscle, in addition to the lowering of plasma glucose. Similar treatment
with tetrandrine reversed the elevated mRNA and protein levels of PEPCK in the liver of STZ-diabetic
rats. The obtained results suggest that tetrandrine may induce the activation of nicotinic receptors in
adrenal medulla to enhance the secretion of  -endorphin, which could stimulate opioid  -receptors to
increase glucose utilization or/and reduce hepatic gluconeogenesis to lower plasma glucose levels in
STZ-diabetic rats.
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derivative work this must be clearly indicated.drug in Oriental countries (2). The principal chemical con-
stituents in Radix Stephania tetrandrae are tetrandrine and
fangchinoline (2). Tetrandrine has been introduced as a calcium
channel blocker (3) and has a wide spectrum of pharmacologi-
cal activities, including the modulation of cardiovascular
disorders (4), anti-tumor (5) and anti-inflammatory effects (6).
Fangchinoline is reported to be less potent than tetrandrine as a
vasodilator or a calcium channel blocker (7). Tetrandrine has
also been reported to have an active oxygen radical scavenging
effect and antioxidant property (8). Moreover, tetrandrine has
been shown to prevent the development of spontaneous diabetes
in BioBreeding rats (9) and protect pancreatic islet beta cells
from the injuries caused by alloxan (10). In addition, we have
observed that tetrandrine has the ability to improve glucose uti-
lization in streptozotocin-induced diabetic rats (STZ-diabetic
rats), the type 1 diabetes-like animal model (11). These results
indicate that tetrandrine seems helpful in the prevention and/or
management of diabetes. However, the mechanism(s) of the
effect of tetrandrine on glucose metabolism remains obscure.
It has been mentioned that exogenous  -endorphin induces
an increase in circulating insulin in humans with or without
diabetes mellitus (12). In fact, the effect of opioid on glucose
homeostasis does not seem to be solely dependent on insulin. In
a previous study (13), we found that  -endorphin may increase
the glucose utilization via opioid  -receptor activation resulting
in the lowering of plasma glucose in STZ-diabetic rats. It seems
that  -endorphin is involved in the regulation of glucose home-
ostasis. Therefore, the aim of this study is to clarify the role of
 -endorphin in the plasma glucose-lowering action of tetran-
drine in diabetic rats lacking insulin.
Materials and Methods
Rats and Mice
Male Wistar rats, weighing 200–250 g, were obtained from the
Animal Center of National Cheng Kung University Medical
College. Male BDF1 mice (as wild-type) and opioid  -receptor
knockout BDF1 mice (14), bred in the same animal center and
aged 8–10 weeks were obtained from Professor H.H. Loh.
Streptozotocin-induced diabetic rats (STZ-diabetic rats) were
prepared by intravenously (i.v.) injecting STZ (60.0 mg/kg)
(Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) into male
Wistar rats, 8–10 weeks of age. Mice with or without opioid 
 -receptors also received an intraperitoneal (i.p.) injection of
STZ at 50.0 mg/kg to induce diabetes according to the previous
method (15). Animals were considered to be diabetic if they
had plasma glucose concentrations of 20 mmol/l or greater in
addition to polyuria and other diabetic features. Plasma insulin
levels in STZ-diabetic rats were reduced to 1.29   0.7 pmol/l
(n   8) following STZ injection, a level markedly lower than
that of the normal rats (160.8   3.7 pmol/l; n   8), indicating
insulin-dependent diabetes mellitus (IDDM). All the studies
were carried out 2 weeks after the injection of STZ. All animal
procedures were performed according to the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health as well as the guidelines of the Animal Welfare Act.
Tetrandrine and Plasma Level of Glucose or 
 -endorphin
After fasting overnight, STZ-diabetic rats received an i.v. injec-
tion of tetrandrine (Sigma-Aldrich, Inc.) at the determined
doses using tetrandrine dissolved in 70% alcohol as stock
solution. In fact, the vehicle (70% alcohol:saline   1:19) used
to prepare tetrandrine solution did not modify the plasma glu-
cose in the preliminary experiments; the basal plasma glucose
was 24.2   1.7 mmol/l and changed to 24.8   2.4 mmol/l in
the vehicle-treated group (n   8). Thus, the effect of the vehi-
cle on plasma glucose of STZ-diabetic rats could be ruled out.
Animals were anesthetized with sodium pentobarbital (30.0
mg/kg, i.p.) and blood samples (0.1 ml) were collected from the
tail vein for the measurement of plasma glucose concentrations
or plasma  -endorphin-like immunoreactivity (BER). In the
preliminary experiments, tetrandrine at 1.0 mg/kg was found to
produce the maximal plasma glucose-lowering effect in STZ-
diabetic rats 30 min after a single i.v. injection. Thus, the effects
of tetrandrine on plasma glucose and plasma BER were deter-
mined using blood samples collected 30 min after the injection.
STZ-diabetic rats that received a similar injection of the same
volume of vehicle (distilled water containing 0.9% [w/v] NaCl)
as that used to dissolve tetrandrine were used as controls.
Further experiments were performed with pharmacological
inhibitors (Research Biochemical Inc., Natick, MA) such as
blockers of nicotinic receptors (hexamethonium or pentolin-
ium) and opioid  -receptor antagonists (naloxone or naloxon-
azine). These inhibitors were injected intravenously into fasted
rats 30 min before the injection of tetrandrine.
Tetrandrine and Plasma Glucose in Opioid 
 -receptor
Fasted STZ-diabetic mice with or without opioid  -receptors
were given an i.v. injection of tetrandrine at a dose of 1.0
mg/kg. After 30 min, blood samples (0.1 ml) were collected
from the lower eye lid of the mice under anesthesia with pen-
tobarbital (30.0 mg/kg, i.p.) using a chilled syringe containing
10 IU heparin.
Isolation and Incubation of Adrenal Medulla
Adrenal glands were quickly removed from the sacrificed STZ-
diabetic rats and medullae were immediately dissected after
removal of the cortex as described previously (16). The tissues
were cut into approximately 1 mm thick slices and transferred
to a glass tube fitted with a nylon mesh at the bottom to permit
free interchange with the medium. The tissues were incubated
for 15 min at 37 C, pH 7.4 and bubbled with a 95% O2 and 5%
CO2 mixture under continuous shaking with 2 ml of modified
Krebs solution (MKS) ([mmol/l]: NaCl 118, KCl 4.7, MgCl2
1.2, NaH2PO4 1.0, CaCl2 2.5, EDTA-Na 0.004, dextrose 11.1,
NaHCO3 25.0 and ascorbic acid 0.11). Tissues were then trans-
ferred to fresh incubation tubes with or without nicotinic recep-
tor antagonists at the indicated concentrations for 15 min at
37 C. They were then incubated with tetrandrine at the indi-
cated concentrations with continuous shaking at 40 cycles/min
194 Antidiabetic action of tetrandrineat 37 C for 30 min. Incubation was terminated by placing the
tubes on ice. The medium from each incubated sample was
collected and frozen at –70 C until the  -endorphin assay was
performed.
Adrenalectomized Rats
Bilateral adrenalectomy was performed in Wistar rats using the
dorsal approach under pentobarbital anesthesia (30.0 mg/kg,
i.p.) as described previously (17). The bilaterally adrenalec-
tomized Wistar rats were also fed standard rat chow and 0.9%
NaCl in their drinking water ad libitum. The sham-operated
Wistar rats served as controls and were fed standard rat chow
and water ad libitum. Animals were allowed to recover for
2 weeks after the operation. The animals appeared alert and in
good health. Following recovery, diabetes was induced by an
injection of STZ as described above. The effect of tetrandrine
at 1.0 mg/kg was determined using blood samples collected
30 min after a single injection as described above.
Laboratory Determinations
The concentration of plasma glucose was measured by the
glucose oxidase method using an analyzer (Quik-Lab, Ames,
Miles Inc., Elkhart, Indiana, USA). The enzyme-linked
immunosorbent assay (ELISA) for the determination of BER
in plasma or in the medium incubating adrenal medulla was
carried out using the commercially available kit (Peninsula
Lab. Inc., CA, USA).
Determination of Gene Expression
STZ-diabetic rats were given injections of the vehicle or
tetrandrine (1.0 mg/kg) every 8 h, three times a day, in the tail
vein. In the preliminary experiments, tetrandrine was found to
significantly modify mRNA and protein levels of glucose
transporters subtype 4 (GLUT4) and hepatic phospho-
enolpyruvate carboxykinase (PEPCK) in STZ-diabetic rats
after a 3-day treatment. Thus, animals were sacrificed after
3 days of treatment. Normal rats received a similar treatment
of the vehicle and were used as controls. After the final treatment,
animals were sacrificed without fasting. Liver and soleus mus-
cle were immediately removed, frozen in liquid nitrogen and
stored at –70 C for Northern and Western blot analysis. Blood
samples were also collected from the tail vein of these rats
before sacrificing to evaluate the change in plasma glucose
concentrations.
Northern Blot Analysis
Total RNA was extracted from soleus muscle or liver of the
experimental animals using the UltraspecTM-II RNA extraction
system (Bioteck, Houston, TE, USA). For Northern blot analy-
sis, RNA (20  g) was denatured in a solution containing
2.2 mmol/l formaldehyde and 50% formamide (v/v) by heating
at 55 C for 15 min. Aliquots of total RNA were size-fractionated
in a 1.2% agarose/formaldehyde gel. Gels were stained with
ethidium bromide to identify the position of the 18S and 28S
rRNA subunits and to confirm that equivalent amounts of
undegraded RNA had been loaded. The RNA was transferred
to a Hybond-N membrane (Amersham, Bucks, UK). GLUT4
and PEPCK mRNA levels were detected using full-length
cDNA probes, radioactively labeled by the random primer
method and hybridized under stringent conditions. Intensity of
the mRNA bands on the blot was quantified by scanning
densitometry (Hoefer, San Francisco, CA, USA). The response
of  -actin was used as an internal standard.
Western Blot Analysis
After homogenization of the liver and soleus muscle using
a glass/Teflon homogenizer, the homogenates (50  g) were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and Western blot analysis was performed
using either anti-rat GLUT4 antibody (1:1000) (Genzyme
Diagnostics, Cambridge, USA) in soleus muscle or anti-rat
PEPCK antibody (1:1000) in liver. The blots were incubated
with mouse monoclonal  -tubulin antibody (1:500) (Zymed
Laboratories, Inc., San Francisco, California, USA) as a control
to ensure that equal amounts of protein were loaded into each
lane of the gel. Blots were incubated with the appropriate per-
oxidase-conjugated secondary antibodies. Following removal
of the secondary antibody, blots were washed as described ear-
lier and developed by autoradiography using the ECL-Western
blotting system. Densities of the obtained immunoblots at
45 KDa for GLUT4, 69.5 KDa for PEPCK and 50 KDa for 
 -tubulin were quantified using a laser densitometer.
Statistical Analysis
The plasma glucose-lowering activity was obtained from the
animals that received tetrandrine. Results of plasma glucose-
lowering activity were calculated as percentage decrease of the
initial value according to the formula: (Gi-Gt)/Gi   100 where
Gi was the initial glucose concentration and Gt was the plasma
glucose concentration after treatment with tetrandrine.
Data are expressed as mean   SE for the number (n) of
animals in the group as indicated in the tables and figures.
Repeated measures analysis of variance (ANOVA) was used to
analyze the changes in plasma glucose and other parameters.
The Dunnett range post-hoc comparisons were used to deter-
mine the source of significant differences where appropriate.
The concentration that produced 50% of the maximum effect
(EC50) was obtained from non-linear regression analysis. 
A P-value  0.05 was considered statistically significant.
Results
Tetrandrine and Plasma Glucose Concentration and
Plasma BER Levels
Thirty minutes after treatment, the plasma glucose-lowering
activity in STZ-diabetic rats was 7.5   1.1%, 15.1   1.4% and
18.4   1.5% in STZ-diabetic rats receiving i.v. injections of
tetrandrine at 0.05 mg/kg, 0.1 mg/kg and 0.5 mg/kg, respec-
tively. The maximal effect (23.8   1.6%) was achieved using
1.0 mg/kg of tetrandrine. Increasing the dose of tetrandrine to
eCAM 2004 1951.5 mg/kg had no further effect. The basal plasma BER level in
STZ-diabetic rats was 43.2   5.5 pg/ml. The time course of the
effect of tetrandrine on the plasma glucose and the secretion of
the plasma BER from STZ-diabetic rats was preliminarily
determined. Similar to the lowering of plasma glucose, plasma
BER level was raised approximately 10 min later in STZ-dia-
betic rats receiving an i.v. injection of tetrandrine at a dose of
1.0 mg/kg. The action of tetrandrine achieved maximal levels
at 30 min, which was used as the optimal time in the following
experiments. A dose-dependent elevation of plasma BER level
was observed in the same group of the STZ-diabetic rats
receiving tetrandrine (Fig. 1) and this action occurred in paral-
lel with the lowering of plasma glucose. Tetrandrine at a dose
of 1.0 mg/kg increased the plasma BER level to 95.7   6.2
pg/ml in STZ-diabetic rats and no further increase in plasma
BER was observed at higher tetrandrine concentrations. 
Thus, 1.0 mg/kg of tetrandrine was employed in subsequent
experiments.
Plasma glucose concentrations of fasting STZ-diabetic rats
were also significantly (P   0.01) decreased to 18.5   1.4
mmol/l after repeated treatment with tetrandrine (1.0 mg/kg)
for 3 days as compared with concentrations in vehicle-treated
STZ-diabetic rats (24.8   1.1 mmol/l). The plasma glucose-
lowering activity was 25.4   2.1% in STZ-diabetic rats after
repeated treatments with tetrandrine at the effective dose.
Moreover, the 3-day treatment with tetrandrine (1.0 mg/kg)
did not influence the feeding behavior and/or body weight of
STZ-diabetic rats.
Opioid  -receptor Antagonists Affects 
Tetrandrine-induced Plasma Glucose-lowering Activity
Table 1 shows the dose-dependent action of naloxone and
naloxonazine to inhibit the plasma glucose-lowering activity of
tetrandrine in STZ-diabetic rats. In the presence of 10.0  g/kg
naloxone, the plasma glucose concentration in STZ-diabetic
rats treated with 1.0 mg/kg tetrandrine was 23.8   2.8 mmol/l,
which was not statistically different from the basal level
(24.2   1.7 mmol/l). As with naloxone, pretreatment with
naloxonazine (10.0  g/kg) prevented the ability of tetrandrine
(1.0 mg/kg) to lower the elevated plasma glucose concen-
trations in STZ-diabetic rats. The plasma glucose level in
the naloxonazine (10.0  g/kg)-pretreated group was 24.0  
2.5 mmol/l, which was near the basal level. Moreover, both
naloxone and naloxonazine at the highest doses did not affect
the basal plasma glucose concentration in STZ-diabetic rats.
Change in Tetrandrine-induced Plasma 
Glucose-Lowering Activity in Opioid  -receptors
As shown in Fig. 2, the plasma glucose concentration of opioid
 -receptor knockout diabetic mice was not modified by tetran-
drine (1.0 mg/kg) treatment (from 25.2   1.8 mmol/l to
24.0   2.2 mmol/l; P   0.05). However, similar treatment
with tetrandrine (1.0 mg/kg) significantly (P   0.05) lowered
the plasma glucose concentration from 23.9   2.2 mmol/l to
18.2   1.9 mmol/l in diabetic mice with opioid  -receptors.
The plasma glucose-lowering activity of tetrandrine in these
wild-type diabetic mice was approximately 23.8   2.1%,
similar to the activity in STZ-diabetic rats.
Tetrandrine-induced Actions in STZ-diabetic 
Rats by Bilateral Adrenalectomy
Two weeks after bilateral adrenalectomy, there were no signif-
icant differences in the basal plasma levels of glucose between
adrenalectomized STZ-diabetic rats and sham-operated con-
trol rats (Table 2). The basal plasma BER was not significantly
different in STZ-diabetic rats that received adrenalectomy as
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Figure 1. The effect of tetrandrine on plasma BER level in STZ-diabetic rats.
Values (means   SE) were obtained from each group of 8 animals receiving
an intravenous (i.v.) injection of tetrandrine at the indicated dose. *P   0.05
and **P   0.01 vs data from animals treated with the vehicle (0) administered
in the same volume.
Table 1. Effects of opioid  -receptor antagonists on tetrandrine-induced
reduction in plasma glucose levels in STZ-diabetic rats
Plasma glucose (mmol/l)
n 7
Basal 24.2   1.7
Tetrandrine (1.0 mg/kg, i.v.)
 Vehicle 18.0   2.1**
  Naloxone ( g/kg, i.v.)
1.0 18.9   1.9**
5.0 20.5   2.5
10.0 23.8   2.8
  Naloxonazine ( g/kg, i.v.)
1.0 19.3   2.2*
5.0 22.6   1.5
10.0 24.0   2.5
Naloxone (10.0  g/kg, i.v.) 23.2   2.6
Naloxonazine (10.0  g/kg, i.v.) 23.7   2.3
Data are means   SE. Basal level shows the value from fasted animals
treated with vehicle. *P   0.05 and **P   0.01 compared with the basal
value, respectively.compared with the sham-operated group; these results are con-
sistent with our previous data (18). However, both the decrease
in plasma glucose and the increase in plasma BER induced by
tetrandrine (1.0 mg/kg) were not observed in STZ-diabetic rats
with bilateral adrenalectomy, while these effects persisted in
the sham-operated STZ-diabetic rats (Table 2).
Tetrandrine Increases the Secretion of BER from
Isolated Adrenal Medulla
The spontaneous secretion of BER from the isolated adrenal
medulla of STZ-diabetic rats was 95.5   7.5 pg/mg protein.
The amount of BER in the medium increased significantly
after incubation with tetrandrine in a concentration-dependent
manner from 0.001  mol/l to 10.0  mol/l (Fig. 3). Tetrandrine
at 1.0  mol/l increased the amount of BER in the medium to
167.4   6.3 pg/mg protein and no further stimulatory effect
was observed at higher tetrandrine concentrations (Fig. 3). The
EC50 of tetrandrine to increase BER secretion from rat adrenal
medulla was approximately 2.6 nmol/l.
Nicotinic Receptor Antagonists on Tetrandrine-induced
Plasma Glucose-lowering Activity
Table 3 shows that the increase in plasma BER by tetrandrine
in STZ-diabetic rats was progressively attenuated in a dose-
dependent manner by hexamethonium or pentolinium given
30 min before the injection of tetrandrine (1.0 mg/kg).
Pretreatment with hexamethonium or pentolinium at 7.5 mg/kg
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Figure 2. Effects of tetrandrine (1.0 mg/kg, i.v.) on plasma glucose concen-
trations in opioid  -receptor knockout mice and wild-type controls. Values
(means   SE) were obtained from each group of 7 animals. **P   0.01 vs
data obtained from animals before treatment in each group.
Figure 3. Effect of tetrandrine on BER secretion from isolated adrenal medulla
of STZ-diabetic rats. Results expressed as pg/mg protein are the means   SE
of 7 determinations. *P   0.05 and **P   0.01 vs data from samples treated
with MKS (0), respectively.
Table 2. Effect of adrenalectomy on the tetrandrine-induced changes in
plasma concentrations in glucose and BER in STZ-diabetic rats
Adrenalectomized Sham-operated 
group group
n 88
Plasma glucose (mmol/l)
Basal 23.8   2.1 24.2   1.8
Vehicle 23.6   2.3 23.9   2.3
Tetrandrine (1.0 mg/kg, i.v.) 23.4   1.8 18.4   1.9**
Plasma BER (pg/ml)
Basal 43.1   4.7 39.9   3.7
Vehicle 42.6   4.3 41.8   4.1
Tetrandrine (1.0 mg/kg, i.v.) 6.1   3.8 94.2   4.9**
Data are means   SE. Basal level shows the value from fasted animals
without treatment. **P   0.01 vs basal value in each group.
Table 3. Effects of nicotinic receptor antagonists on the tetrandrine-induced
changes in BER and glucose concentrations in plasma of STZ-diabetic rats
Plasma glucose  Plasma BER 
(mmol/l) (pg/ml)
n 88
Basal 24.8   1.5 39.3   2.5
Tetrandrine (1.0 mg/kg, i.v.)
 Vehicle 18.7   1.8** 96.1   5.8**
  Hexamethonium (mg/kg, i.v.)
2.5 20.4   2.3* 90.3   4.8**
5.0 22.5   1.9 70.2   4.6*
7.5 23.8   1.6 42.0   5.7
  Pentolinium (mg/kg, i.v.)
2.5 21.0   2.0 85.2   5.3**
5.0 23.1   1.8 62.5   6.0*
7.5 24.2   1.7 39.3   5.2
Hexamethonium (7.5 mg/kg, i.v.) 24.6   2.4 38.5   4.9
Pentolinium (7.5 mg/kg, i.v.) 25.1   2.9 37.2   5.1
Data are means   SE. Basal level shows the value from fasted animals
treated with vehicle. *P   0.05 and **P   0.01 compared with basal value,
respectively.completely abolished the activity of tetrandrine. Moreover,
hexamethonium or pentolinium at the effective dose of 
7.5 mg/kg failed to influence the basal plasma BER level in
STZ-diabetic rats.
Similar to the effect on plasma BER, the plasma glucose-
lowering activity of tetrandrine at 1.0 mg/kg was decreased
in a dose-dependent manner in the presence of hexametho-
nium. Pretreatment with hexamethonium at the highest dose
(7.5 mg/kg) completely abolished the plasma glucose-lowering
activity of tetrandrine. Similarly, the plasma glucose-lowering
activity of tetrandrine (1.0 mg/kg) in STZ-diabetic rats was
attenuated by pretreatment with pentolinium. However, no
change in plasma glucose concentration was found in STZ-
diabetic rats that received either antagonist alone at maximal
doses (Table 3).
Nicotinic Receptor Antagonists Blocks 
Tetrandrine-stimulated BER Secretion from Isolated
Adrenal Medulla of STZ-diabetic Rats
Table 4 shows that both hexamethonium and pentolinium
blocked the tetrandrine-stimulated BER secretion from isolated
rat adrenal medulla in a concentration-dependent manner. 
Pre-incubation with hexamethonium at 1.0  mol/l reduced BER
secretion induced by 1.0  mol/l tetrandrine from 160.7   6.1 to
95.7   6.2 pg/mg protein. This was not different from the basal
value (90.2   5.8 pg/mg protein) obtained from vehicle-treated
samples. Further, pentolinium at 1.0  mol/l reversed the
increase in BER secretion stimulated by tetrandrine (1.0  mol/l)
to the basal level. However, hexamethonium or pentolinium, at a
concentration (1.0  mol/l) sufficient to completely block nico-
tinic receptors, did not modify the spontaneous secretion of BER
from the isolated adrenal medulla of STZ-diabetic rats (Table 4).
Tetrandrine Elevates the mRNA and Protein Levels of
GLUT4 in Soleus Muscle
Similar to our previous study (Cheng et al., 2001b), the mRNA
level of GLUT4 in isolated soleus muscle from vehicle-treated
STZ-diabetic rats was approximately 45% of that of vehicle-
treated normal rats (Fig. 4). Repeated treatment of STZ-diabetic
rats with tetrandrine (1.0 mg/kg) for 3 days resulted in an
elevation of GLUT4 mRNA level in soleus muscle to a level
approximately 77% of that of vehicle-treated normal rats.
However, similar treatment with tetrandrine (1.0 mg/kg) in nor-
mal rats did not (P   0.05) modify the mRNA level of GLUT4
as compared with vehicle-treated normal rats (data not shown).
The protein level of GLUT4 in soleus muscle of vehicle-
treated STZ-diabetic rats was significantly reduced to approxi-
mately 50% of that of the vehicle-treated normal rats (Fig. 4).
Similar to the effect on mRNA level, repeated oral treatment
with tetrandrine (1.0 mg/kg) significantly elevated the protein
level of GLUT4 in soleus muscle of STZ-diabetic rats to a level
approximately 82% of that of vehicle-treated normal rats.
However, similar treatment with tetrandrine (1.0 mg/kg) in
normal rats did not (P   0.05) modify the mRNA and protein
level of GLUT4 in isolated soleus muscle as compared with the
vehicle-treated normal rats (data not shown). Quantification of
the mRNA and protein level for GLUT4 are shown in Table 5.
Tetrandrine Elevates the mRNA and Protein Levels of
Hepatic PEPCK
Figure 5 shows that the mean level of mRNA encoding PEPCK
was elevated nearly 2.3-fold in untreated STZ-diabetic rats as
compared with normal rats; this is consistent with our previous
data (19). This increase in the mRNA level in the liver of STZ-
diabetic rats was inhibited to about 66% of the vehicle-treated
STZ-diabetic rats by repeated treatment with tetrandrine
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Table 4. Effects of nicotinic receptor antagonists on tetrandrine-induced
changes in BER in isolated adrenal medulla of STZ-diabetic rats
BER (pg/mg protein)
n 7
Basal 90.2   5.8
Tetrandrine (1.0  mol/l)
 Vehicle 160.7   6.1**
  Hexamethonium ( mol/l)
0.01 140.7   9.5**
0.1 121.2   7.3*
1.0 95.7   6.2
  Pentolinium ( mol/l)
0.01 133.5   8.3**
0.1 111.9   6.7*
1.0 91.3   7.9
Hexamethonium (1.0  mol/l) 89.8   6.1
Pentolinium (1.0  mol/l) 87.1   8.2
Data are means   SE. *P   0.05 and **P   0.01 compared with basal value
obtained from samples only treated with vehicle (MKS), respectively.
A
B
Figure 4. A: Representative response of mRNA level for GLUT4 or  -actin in
soleus muscle isolated from normal or STZ-diabetic rats receiving repeated
treatment with tetrandrine (1.0 mg/kg) or the same volume of vehicle three times
a day for 3 days. B: Identification of protein level of GLUT 4 or  -tubulin using
immunoblot analysis. Lanes show vehicle-treated normal rats (lane 1), vehicle-
treated STZ-diabetic rats (lane 2) and tetrandrine-treated STZ-diabetic rats 
(lane 3).(1.0 mg/kg), although the value was still higher than that of
vehicle-treated normal rats. Similar treatment with tetrandrine
(1.0 mg/kg) in normal rats did not (P   0.05) modify the
mRNA level of hepatic PEPCK as compared with the vehicle-
treated normal rats (data not shown).
In parallel with the data from mRNA, the protein level of
PEPCK in the liver of vehicle-treated STZ-diabetic rats was
approximately 2.3-fold of the vehicle-treated normal rats.
Repeated treatment of STZ-diabetic rats with tetrandrine
resulted in a marked reduction in the protein level of PEPCK
to approximately 60% of that of vehicle-treated STZ-diabetic
rats (Fig. 5). Meanwhile, the hepatic PEPCK protein levels in
normal rats pretreated with tetrandrine were unchanged when
compared with those in the vehicle-treated group (data not
shown). Quantification of the protein level for PEPCK is
shown in Table 5.
Discussion
In the present study, we found that tetrandrine can dose-
dependently increase the plasma BER in STZ-diabetic rats in
a manner parallel to the lowering of plasma glucose as men-
tioned in our previous report (11). In STZ-diabetic rats, the
deficiency of insulin has been documented (20). In the present
study, the plasma insulin level in STZ-diabetic rats was only
approximately 1/120 of that in normal rats. Thus, mediation
of endogenous insulin is negligible in this STZ-diabetic rat
model. In fact, plasma glucose-lowering activity is not entirely
dependent on insulin regulation; for example, physical exer-
cise is traditionally considered beneficial in the treatment of
diabetes (21). In addition, our previous reports (16,18,19,22)
indicated that activation of opioid  -receptors plays a role in
the regulation of glucose metabolism during an insulin-
deficient state. The physiological actions of endogenous 
 -endorphins are mediated in part by opioid  -receptors (23).
Therefore, an elevation of endogenous  -endorphin that can
activate the opioid receptors seems related to the plasma
glucose-lowering activity of tetrandrine in STZ-diabetic rats.
Although  -endorphin is released along with adrenocorti-
cotrophic hormone from the pituitary gland (24), the adrenal
gland is also a source of  -endorphin (25,26). Our previous
reports have demonstrated that secretion of opioids from the
adrenal gland is associated with a decrease in plasma glucose
in STZ-diabetic rats (16,18,22), which is consistent with the
view that pituitary gland-independent release of endogenous
opioids is operative in other organs (25,26). In an attempt to
identify the adrenal gland as the source of tetrandrine-induced
release of  -endorphin, adrenalectomy was performed in STZ-
diabetic rats. We found that the plasma glucose-lowering
activity of tetrandrine was abolished following bilateral
adrenalectomy in STZ-diabetic rats. Moreover, no increase in
plasma BER was observed in adrenalectomized diabetic rats
that received tetrandrine at the effective doses. Thus, secretion
of endogenous  -endorphin from the adrenal gland is likely to
be responsible for the plasma glucose-lowering action of
tetrandrine in STZ-diabetic rats.
Splanchnic nerve stimulation increases the release of opioids
from the adrenal gland into the adrenal vein (27,28). The
release of opioids appears to be mediated by a cholinergic
nicotinic receptor (27,28). In the presence of hexamethonium
or pentolinium, antagonists specific for the nicotinic receptor,
the plasma glucose-lowering activity of tetrandrine was
blocked in a dose-dependent manner. Moreover, the increase
in plasma BER by tetrandrine was sensitive to both nicotinic
receptor antagonists. Therefore, mediation of the adrenal nico-
tinic receptor activation seems responsible for the increase in
endogenous  -endorphin secretion by tetrandrine. The direct
effect of tetrandrine on the secretion of  -endorphin was also
characterized using isolated adrenal medulla. We found that
tetrandrine enhanced BER secretion from isolated adrenal
medulla of STZ-diabetic rats in a concentration-dependent
manner. In addition, hexamethonium or pentolinium inhibited
the tetrandrine-stimulated secretion of BER, indicating that
tetrandrine may enhance  -endorphin secretion in the adrenal
medulla via an activation of nicotinic receptors. These results
are consistent with the finding that nicotinic receptors play a
role in the regulation of adrenal  -endorphin release (27,28).
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Table 5. Quantification of the mRNA and protein levels for GLUT4 in
isolated soleus muscle and hepatic PEPCK from STZ-diabetic rats repeatedly
treated with tetrandrine
Normal rats, STZ-diabetic rats
vehicle- Vehicle- Tetrandrine-
treated treated treated
n 66 6
GLUT4 (arbitrary units)
mRNA/ -actin 1.63   0.05 0.72   0.06** 1.25   0.05*
Protein/ -tubulin 1.49   0.04 0.75   0.05** 1.23   0.06*
PEPCK (arbitrary units)
mRNA/ -actin 1.31   0.06 2.95   0.08** 1.95   0.07*
Protein/ -tubulin 1.22   0.04 2.85   0.06** 1.77   0.06*
Data are means   SE. *P   0.05 and **P   0.01 compared with vehicle-
treated normal rats.
Figure 5. A: Representative response of mRNA level for PEPCK or  -actin
in liver isolated from normal or STZ-diabetic rats receiving repeated treatment
with tetrandrine (1.0 mg/kg) or the same volume of vehicle three times daily
for 3 days. B: Identification of protein level of PEPCK or  -tubulin using
immunoblot analysis. Lanes show vehicle-treated normal rats (lane 1), vehi-
cle-treated STZ-diabetic rats (lane 2) and tetrandrine-treated STZ-diabetic rats
(lane 3).
A
BRecently, we observed that activation of opioid  -receptors
in peripheral tissues lowers plasma glucose by improving
glucose utilization during the insulin deficient state (19). The
response to tetrandrine in STZ-diabetic rats was inhibited
by blockade of opioid  -receptors using naloxone or naloxon-
azine. In addition, we employed opioid  -receptor knockout
mice receiving STZ to confirm the role of opioid  -receptors
in the action of tetrandrine. In contrast to wild-type diabetic
mice having opioid  -receptors, the plasma glucose-lowering
activity of tetrandrine was depleted in opioid  -receptor
knockout diabetic mice. These data suggest that opioid  -
receptors play a role in the plasma glucose-lowering activity of
tetrandrine under the insulin deficient state.
In diabetes, elevation of blood glucose is a consequence of
increased hepatic glucose output together with reduced periph-
eral glucose utilization (29). Skeletal muscle is a major site of
glucose disposal (30). Glucose transportation, which depends
on insulin-stimulated translocation of glucose carriers to the cell
membrane, is the rate-limiting step in carbohydrate metabo-
lism of skeletal muscle (31). A family of glucose transporters
(GLUT) mediates glucose transport across the cell membrane,
and the subtype named GLUT4 is predominant in skeletal mus-
cle (32). Reduction in insulin-mediated glucose uptake resulting
from decreased expression of GLUT4 mRNA and protein in
diabetes has been reported (33). In a previous study, we found
that the plasma glucose-lowering activity of tetrandrine was
associated with the enhancement of glucose uptake and glyco-
gen synthesis in STZ-diabetic rats (11). Moreover, we have
demonstrated that endogenous  -endorphin via the activation of
the opioid  -receptors is a positive regulator of glucose utiliza-
tion and a negative modulator of hepatic gluconeogenesis in the
insulin deficient state (19,22). In STZ-diabetic rats, plasma glu-
cose levels were reduced by a 3-day repeated treatment with
tetrandrine. Since long-term exposure is required for the activa-
tion of mRNA levels (34), GLUT4 gene expression was exam-
ined in STZ-diabetic rats that received a 3-day repeated
treatment with tetrandrine. We found that both the mRNA and
protein levels of GLUT4 were increased by tetrandrine after
repeated injections for 3 days. Thus, it is reasonable to specu-
late that an increase in the gene expression of GLUT4 may con-
tribute to the enhancement of glucose utilization after repeated
tetrandrine treatment. It has been documented that phospholi-
pase C (PLC) and protein kinase C (PKC) play a key role in the
signals of opioid  -receptors (23). Moreover, it has been indi-
cated that PKC is involved in the rate-limiting step in GLUT4
mRNA expression (32). Therefore, the PLC-PKC pathway is
related to the signals of opioid  -receptors in the regulation of
GLUT4 gene expression although an understanding of the
detailed mechanism needs further investigations.
Mammalian cells store glycogen in the liver for using it in
the production of glucose 6-phosphate in glycolysis (35).
PEPCK, which catalyzes a regulatory step in gluconeogenesis,
is one of the key enzymes in hepatic carbohydrate metabolism
(36). Studies on diabetic animals have shown that augmented
gluconeogenesis is a major factor in the increased plasma
glucose that appears in the fasting and postabsorptive states
(29). In the present study, the enhanced gene expression of
PEPCK resulting in increases in mRNA and protein levels in
diabetic rats was suppressed by a 3-day repeated treatment
with tetrandrine. Thus, the decrease in PEPCK appeared to be
also related to the plasma glucose-lowering activity of tetran-
drine. Since gene expression of PEPCK in liver is regulated by
a number of hormones (36), further experiments are necessary
to identify the hormones involved in the effect of tetrandrine
on the hepatic gene expression of PEPCK. Opioid  -receptor
activation might act as a negative regulator modifying the gene
expression of PEPCK in the insulin deficient state. In fact, it
has been mentioned that signals for insulin to inhibit PEPCK
expression did not mediate through the PKC pathways (36).
Signals for opioid  -receptors to regulate the hepatic PEPCK
gene expression need to be clarified in the future.
Long-term treatment of dogs with tetrandrine at a higher oral
dose of 40.0 mg/kg may induce focal necrosis of liver cells
(37). However, the beneficial effect of tetrandrine at an oral
dose of 10 mg/kg per day on experimental hepatic fibrosis
induced by bile duct ligation and scission in rats has also been
documented (38). In the present study, the dose of tetrandrine
effective in lowering the plasma glucose or increasing the
plasma BER in STZ-diabetic rats is less than that required to
produce these effects in liver (37,38). A 3-day repeated treat-
ment with tetrandrine did not lead to toxicity in STZ-diabetic
rats. Thus, tetrandrine may be useful in the future for thera-
peutic control of type 1 diabetes.
In conclusion, our results suggest that activation of nicotinic
receptors in the adrenal medulla by tetrandrine may enhance
the secretion of endogenous  -endorphin from the adrenal
gland of STZ-diabetic rats. The plasma glucose-lowering
activity of tetrandrine was mediated by the release of  -endor-
phin to stimulate opioid  -receptors, thereby increasing glu-
cose utilization in peripheral tissues by an increase in GLUT4
gene expression and/or an attenuation of elevated hepatic
PEPCK gene expression. Therefore, an improvement in glu-
cose utilization in peripheral tissues and the decline of hepatic
gluconeogenesis resulting in the decrease of plasma glucose
by tetrandrine in STZ-diabetic rats is mainly mediated by
endogenous  -endorphin.
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